Anti-Muellerian hormone (AMH) as only possible marker in the assessment of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females receiving hormonal replacement therapy

Bone Marrow Transplant. 2017 Feb;52(2):313-316. doi: 10.1038/bmt.2016.273. Epub 2016 Nov 14.

Authors

A Wędrychowicz¹, J Wojtyś¹, J Starzyk¹

Affiliation

¹ Department of Pediatric and Adolescent Endocrinology, Pediatric Institute, Medical College, Jagiellonian University in Krakow, Cracow, Poland.

PMID: 27841859
DOI: 10.1038/bmt.2016.273

No abstract available

Publication types

Clinical Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Allografts
Anti-Mullerian Hormone / blood*
Child
Female
Hematologic Neoplasms / blood
Hematologic Neoplasms / pathology
Hematologic Neoplasms / physiopathology
Hematologic Neoplasms / therapy
Hematopoietic Stem Cell Transplantation*
Hormone Replacement Therapy*
Humans
Hypogonadism* / blood
Hypogonadism* / therapy
Ovary / metabolism*
Ovary / physiology
Ovary / physiopathology

Substances

Anti-Mullerian Hormone